Plasma B-type Natriuretic Peptide Levels in Congenital Heart Diseases.
Background: B type natriuretic peptide (BNP) and its precursor, the inactive form of NT-pro-BNP, are currently the
most studied laboratory parameters in the heart disease spectrum. The assessment of their blood concentrations
provides valuable information on the severity and prognosis of the disease.
Aim: to evaluate plasma B-type natriuretic peptide levels in paediatric patients with congenital heart disease and to
asses its value as diagonstic and prgnostic marker.
Patients and methods:This is a cross-sectional, case-control, hospital based study carried out on 31 pediatric cardiac
patients enrolled from NICU and pediatric department of Qena university hospital between August 2017 and
November 2018. Additionally, 30 healthy age and sex-matched were used as controls. Echocardiography has been
performed to all included children, in addition to plasma BNP measurments using ELISA kit.
Result(s): Overall results showed that the frequency of multiple congenital anomalies was 38.7%, followed by
isolated VSD (25.8%), while isolated PDA has the least frequency (6.5%). There was significantly higher mean
plasma BNP levels among pediatric patients with CHD versus the controls (19.36 ± 19.73, 2.99±1.25 respectively,
Conclusion: These results suggest the possible role of plasma BNP as a significant marker in diagnosing pediatric
patients with CHD.